Catalyst
Slingshot members are tracking this event:
bluebird bio's (BLUE) Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel bb2121 - KarMMa) in Relapsed/refractory multiple myeloma PDUFA date set for March 27, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BLUE | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 26, 2021
Occurred Source:
https://investor.bluebirdbio.com/news-releases/news-release-details/us-food-and-drug-administration-approves-bristol-myers-squibbs
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ide-cel Bb2121, Karmma, Idecabtagene Vicleucel, Anti-bcma Car T Cell Therapy, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
